Updated Articles

  1. Who owns the MBG output?

    All outputs from the model will be owned by the countries whose data were used to generate them.
  2. When will we have official confirmation from WHO/Tropical Data to use MBG?

    MBG was officially confirmed as an acceptable method to demonstrate that TT prevalence was below the elimination threshold at the 4th Global Scientific Meeting on Trachoma in 2018 (https://www.who.int/publications/i/item/who-htm-ntd-pct-2019.03) a...
  3. Is there any support available for health ministries interested in implementing MBG?

    Currently, the MBG models require intensive computations and the larger the datasets that have to be processed, the longer it takes - some take up to a week to generate results! It is therefore not yet possible for Tropical Data or Lancaster Univers...
  4. Where is the funding coming from to support the research and the Tropical Data development?

    Funding is currently provided by the United States Agency for International Development (USAID) via the Task Force for Global Health, until May 2024.
  5. Is it possible to use MBG for an entire country?

    Theoretically yes, it is possible, however it would be context dependent. To date, MBG has been implemented to estimate trachoma prevalence for a specific area (usually an individual EU) by using data from a wider area within the same country. We ...
  6. Can MBG be used for islands in an archipelago community?

    This would depend entirely on the spatial relationship of trachoma amongst the different islands.   If there was strong spatial correlation between islands it may be possible to use MBG, however this would need to be reviewed on a case-by-cas...
  7. Can MBG be used when there is large population movement?

    When there is large population movement within an EU, one of the challenges for the models is trying to incorporate more assumptions and to account for more variation than normal, and this leads to a lot of uncertainty. It may be possible to accou...
  8. Can MBG be used to estimate prevalence in inaccessible EUs?

    MBG has not yet been used to estimate prevalence in inaccessible EUs, however, it is theoretically possible to do this when there are enough existing data in nearby EUs to estimate trachoma prevalence in the area of interest. There would need to b...
  9. What is required in order to run MBG?

    Permission to use country-specific prevalence data is needed, with access provided to the individual-level data contained in all relevant datasets. The surveys must have been supported by the Global Trachoma Mapping Project (GTMP) and/or Tropical ...
  10. How has MBG been used so far within the context of trachoma elimination?

    To date, MBG has been used to create a geostatistical survey design to quantify the likelihood that TT prevalence at EU-level is below the TT elimination threshold (See publications folder for relevant papers supporting this). It has also been use...